CCR2 and malignant pleural mesothelioma: Moreover, given the high levels of chemokines that are present in TME, clinical studies based on the use of CD2/CCR2b engineered CAR T cells and mesothelin CAR/CCR2 T cells showed a migration and homing increase of the CAR T ranging bethween 10- and 12-fold into neuroblastoma tumors and malignant pleural mesothelioma, respectively [102,103].